BioAdvance News

Niiki Pharma Announces the Completion of Phase I Dose Escalation for First-in-Man Anti-Cancer Agent NKP-1339

By WebmasterJanuary 17, 2012November 1st, 2024No Comments

Niiki Pharma Announces the Completion of Phase I Dose Escalation for First-in-Man Anti-Cancer Agent NKP-1339
Read more here

Previous PostCeptaris Therapeutics Receives EMA Orphan Drug Designation for Proprietary Mechlorethamine Gel
Next PostNiiki Pharma Developing New Weapons to Battle Cancer